Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...
Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...
While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...
The federal crackdown on DEI initiatives is unlikely to deter companies from designing more representative trials, as it’s ...
(Reuters) -Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for ...
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price in January. But this ...
For decades, researchers have worked to create drugs that teach the immune system to kill cancer cells the way traditional ...
Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...
Eikon Therapeutics is no stranger to eye-popping funding rounds, and the cancer-focused biotech has continued this trend with ...
The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...
Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on DNA-damage response technologies, proudly reaffirms its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback